Endobetix

Company Overview

Snapshot

Founded in August 2012 by Chen Porat, Endobetix operates with 1–10 employees. The company has raised $650,000 across one funding round. In July 2015, Endobetix was awarded a U.S. patent, marking a significant intellectual property milestone.

Business overview

Endobetix is a Health Tech & Life Sciences company developing a minimally invasive, non-surgical implant designed to treat Type 2 Diabetes and obesity. Its core product, the Endobetix Bile Diversion Device (BDD), is an endoscopically implantable solution that reroutes bile and pancreatic secretions to alter hormonal balance, improve glucose tolerance, and reduce fat absorption. The company targets the medical devices sector, serving hospitals and doctors with solutions in gastroenterology and obesity treatment.

Strategic signal

In July 2015, Endobetix secured a U.S. patent for its technology. This patent provides a strong validation of the company's innovative approach to treating Type 2 Diabetes and obesity, signaling to investors the proprietary nature and potential market defensibility of its minimally invasive Bile Diversion Device.

Company Intelligence Q&A

What is Endobetix's primary focus?

Endobetix focuses on developing a minimally invasive, non-surgical implant for the treatment of Type 2 Diabetes and obesity.

When was Endobetix founded?

Endobetix was founded in August 2012.

What is the Endobetix Bile Diversion Device (BDD)?

The BDD is an endoscopically implanted device that reroutes bile and pancreatic secretions to improve glucose tolerance and reduce fat absorption by changing hormonal balance.

What significant intellectual property milestone did Endobetix achieve?

In July 2015, Endobetix was awarded a U.S. patent for its technology, providing strong validation of its innovative approach to treating Type 2 Diabetes and obesity.

Which award was Endobetix a finalist for in 2015?

In April 2015, Endobetix was a finalist for the Red Herring Top 100 Europe Award.